NCT02718820View on ClinicalTrials.gov

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Head and Neck Carcinoma
Interventions
DRUG

Docetaxel

Docetaxel 75mg/m2; q21

DRUG

Pembrolizumab

Pembrolizumab 200mg, q21

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02718820 - Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter